Literature DB >> 16115129

Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma.

Laura Rosiñol1, Ana Carrió, Joan Bladé, Rosa Queralt, Marta Aymerich, Ma Teresa Cibeira, Jordi Esteve, Maria Rozman, Elías Campo, Emili Montserrat.   

Abstract

Two variants of smoldering multiple myeloma (SMM) have been recognised: (i) an evolving type, characterised by a progressive increase in the M-protein size and short time to progression to overt multiple myeloma (MM) and (ii) a non-evolving type, with a long-lasting, stable M-protein and longer time to progression. Comparative genomic hybridisation (CGH) analyses in both subtypes of SMM (seven evolving and eight non-evolving SMM) were performed. Evolving SMM showed cytogenetic changes consistent with those found in de novo symptomatic MM (1q gains, chromosome 13 deletions) while the non-evolving variant showed no 1q gains and deletions were uncommon.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16115129     DOI: 10.1111/j.1365-2141.2005.05673.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  Genomic analysis of high-risk smoldering multiple myeloma.

Authors:  Lucía López-Corral; María Victoria Mateos; Luis A Corchete; María Eugenia Sarasquete; Javier de la Rubia; Felipe de Arriba; Juan-José Lahuerta; Ramón García-Sanz; Jesús F San Miguel; Norma C Gutiérrez
Journal:  Haematologica       Date:  2012-02-13       Impact factor: 9.941

2.  The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.

Authors:  Fiona M Ross; Laura Chiecchio; GianPaolo Dagrada; Rebecca K M Protheroe; David M Stockley; Christine J Harrison; Nicholas C P Cross; Alex J Szubert; Mark T Drayson; Gareth J Morgan
Journal:  Haematologica       Date:  2010-04-21       Impact factor: 9.941

Review 3.  The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.

Authors:  Sarah K Johnson; Christoph J Heuck; Anthony P Albino; Pingping Qu; Qing Zhang; Bart Barlogie; John D Shaughnessy
Journal:  Int J Hematol       Date:  2011-10-15       Impact factor: 2.490

4.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

Review 5.  High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.

Authors:  Chutima Kunacheewa; Elisabet E Manasanch
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-25       Impact factor: 3.020

6.  Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

Authors:  Fenghuang Zhan; Bart Barlogie; Varant Arzoumanian; Yongsheng Huang; David R Williams; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Maurizio Zangari; Madhav Dhodapkar; John D Shaughnessy
Journal:  Blood       Date:  2006-10-05       Impact factor: 22.113

Review 7.  Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.

Authors:  Ola Landgren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

Review 8.  Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.

Authors:  Joan Bladé; Meletios Dimopoulos; Laura Rosiñol; S Vincent Rajkumar; Robert A Kyle
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

9.  Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case.

Authors:  Laura Chiecchio; Gian Paolo Dagrada; Rebecca K M Protheroe; David M Stockley; Alastair G Smith; Kim H Orchard; Nicholas C P Cross; Christine J Harrison; Fiona M Ross
Journal:  Haematologica       Date:  2009-05-19       Impact factor: 9.941

Review 10.  The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Authors:  Y Zhou; B Barlogie; J D Shaughnessy
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.